RE:RE:RE:RE:RE:RE:RE:RE:RE:OHHHH DEAR.... TD JUST CUT TO HOLD FROM BUYDo you know how it reimbursements work in the US ? A retailer of drugs, CVS for instance, can sell a product and not be covering it. If it's not included in Medicaid or Medicare, governments programs, it will be expensive, but some folks need it anyway and will try to get it covered with their private insurances. CVS removed it because new alternatives are coming out at a cheaper price. That's ANI Pharmarceuticals's generic of Nilandron.
visionaryfool wrote: Not sure if you read the news release but it pretty much says "F*** CVS" given they don't do any volumes with them anyways. This, IMHO, was CVS's way to show some progress to customers but the impact will be from other drugs, not these ones.
Also, not all pharmacy's are treated the same. Pricing is dynamic so it could very well be that Express / others might get a better deal already.
Sufficient to say that the Q2 call will be informative I think so best to wait till next Friday to find out whats happening instead of speculating.
CNInvesting wrote: Also of note is that I don't know who the heck that extra sales team will try to sell Nilandron when CVS has officially bared them saying :
“CVS Health is taking a stand against egregious drug price increases that unnecessarily add costs for clients and their members,” the PBM said.''
Why would any other retailer buy this product, for instance ExpressScript, if their competitor is saying on the record that it's too expensive for clients ? CXR would have to give them a few incentives aka price cuts. Anway.